In the literature, many reports and clinical trials have shown that anti-VEGF therapy alone is more effective in reducing the central macular thickness and improving visual acuity due to diabetic macular edema [7–10] as also in improving the level of retinopathy due to VEGF inhibition when compared with anti-VEGF therapy alone or with/without laser photocoagulation [7–10]. The gene discussed is VEGFA; the disease is diabetic macular edema.